A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)

A Phase 3 Study to Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis (ENLIGHTEN)

A Phase 3 Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH (ENLIGHTEN-Cirrhosis)

A randomized, double-blind, placebo-controlled, multicentre Phase 3 trial evaluating long-term efficacy and safety of weekly survodutide injections in adults with MASH/NASH and F2–F3 liver fibrosis

A Phase 3 double-blind, randomized, placebo-controlled trial evaluating liver-related clinical outcomes and safety of once-weekly survodutide in participants with compensated MASH/NASH cirrhosis

SYNERGY-Outcomes – A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in Adults With MASLD at Increased Risk of Major Adverse Liver Outcomes

ZENITH-1 – A Phase 3 study of efimosfermin alfa in participants with biopsy-confirmed F2- or F3-stage MASH

ZENITH-2 – A Phase 3 study to investigate the safety and tolerability of efimosfermin alfa in participants with known or suspected F2- or F3-stage MASH

Phase 3 Study of Barzolvolimab in Participants with Cold Induced Urticaria and Symptomatic Dermographism

Phase 3 Efficacy and Safety of Lebrikizumab in Adults With Nummular Eczema (LUMINE)

A Phase 3 Multicenter, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lutikizumab in Adult and Adolescent Subjects With Moderate to Severe Hidradenitis Suppurativa

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)

Selective Treatment of Oral Povorcitinib Long-Term Rollover Study (STOP-LTR)

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Galvokimig in Adults With Moderate to Severe Atopic Dermatitis

A Phase 3 Study of Barzolvolimab in Patients With Chronic Spontaneous Urticaria (EMBARQ-CSU1)

Efficacy and Safety of Once Daily Oral Semaglutide in Adults With Overweight or Obesity (OASIS 5)

A Randomized, Multicenter, Double-Blind, Placebo-Controlled Development Program to Evaluate the Efficacy and Safety of LY4268989 (MORF-057) for the Treatment of Adults With Moderately to Severely Active Ulcerative Colitis (EMERALD-3)

A Follow-up Phase II Open-label Study to Evaluate the Long-term Safety and Efficacy Profile of ABX464 in Moderate to Severe Active Ulcerative Colitis

LUMINA 3 – A Phase 3 Study of Rilzabrutinib in Participants With Warm Autoimmune Hemolytic Anemia

BaxDuo Prevent-HF – Phase 3 trial of baxdrostat + dapagliflozin to reduce heart failure and cardiovascular death

PREVAIL – Placebo-Controlled, Double-Blind, Randomized Cardiovascular Outcome Study of Obicetrapib in Participants With ASCVD

LIBREXIA-AF – A Phase 3 Active-Controlled Study of Milvexian for Prevention of Cardioembolic Events in Participants With Atrial Fibrillation

A Phase III Study of Vicadrostat (BI 690517) in Combination With Empagliflozin in Heart Failure With LVEF ≥40%

EASi-HF reduced – A Phase III Study of Vicadrostat (BI 690517) + Empagliflozin in Chronic Heart Failure With LVEF <40%

ZENITH – A Phase 3 Study of Zilebesiran in Addition to Standard of Care in Hypertension

A Phase 3, Randomized, Multicenter, Double-blind Study to Assess Stroke and Systemic Embolism Prevention with REGN7508, a Monoclonal Antibody Against Factor XI, Versus Apixaban in Participants with Atrial Fibrillation (ROXI-EVEREST)

A Master Protocol for a Phase 3, Randomized, Multicenter, Double-blind Study to Assess Stroke and Systemic Embolism Prevention With REGN7508 and REGN9933, Monoclonal Antibodies Against Factor XI, Versus Placebo in Participants With Atrial Fibrillation for Whom Oral Anticoagulation is Unsuitable (ROXI-INCLINE)

A Multicentre, Single-Arm, Phase 3b Study to Assess Changes in Symptoms in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps Initiating Treatment With Tezepelumab (ESSENCE)

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 52-Week Phase 3 Trial to Investigate Itepekimab in Adults With Inadequately Controlled Chronic Rhinosinusitis With Nasal Polyps

Long-term effects of semaglutide on diabetic retinopathy in subjects with type 2 diabetes (FOCUS)

REVEAL-2 – A Phase 3 Study of VRDN-003 in Participants With Chronic Thyroid Eye Disease

Phase 3 Study of VRDN-003 in Participants With Chronic Thyroid Eye Disease

A Phase III, Randomized, Double-Masked, Placebo-Controlled Study to Evaluate the Efficacy of MHB018A Injection Treatment in Subjects With Active Moderate to Severe Thyroid Eye Disease.

A Phase III, Randomized, Double-Masked, Placebo-Controlled Study to Evaluate the Efficacy of MHB018A Injection Treatment in Subjects With Chronic Moderate-to-Severe Thyroid Eye Disease

Clinical Study to Compare Efficacy and Safety of AVT29 and Eylea HD in Participants With Diabetic Macular Edema

A Randomized, Double-Blind, Placebo-Controlled, Pivotal Phase 3 Study to Evaluate the Long-Term Efficacy and Safety of Multiple Maintenance Doses of Once Daily Oral Aleniglipron for Chronic Weight Management in Adults With Obesity or Overweight and a Weight-Related Comorbidity

A Long-Term Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Multiple Maintenance Doses of Oral Once Daily Aleniglipron for Chronic Weight Management in Adults with Obesity or Overweight and Type 2 Diabetes Mellitus

Evaluating the Efficacy and Safety of MET097, a Fully-Biased, Ultra Long-Acting GLP-1RA, in People With Overweight or Obesity – VESPER-4

Evaluating the Efficacy and Safety of MET097 in People With Overweight or Obesity and Type 2 Diabetes – VESPER-5

A PHASE III, RANDOMIZED, DOUBLE - BLIND, PLACEBO - CONTROLLED, PARALLEL GROUP STUDYTO EVALUATE THE EFFICACY AND SAFETY OF ONCE WEEKLY PETRELINTIDE VS. PLACEBO IN PARTICIPANTS WITH OVERWEIGHT OR OBESITY

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)

RENEW-MDD-2 – A Phase 3 study of brenipatide in adults with major depressive disorder

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of KT-621 in Adults With Uncontrolled Moderate to Severe Eosinophilic Asthma

VIGILANT – A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Early Depemokimab Initiation in COPD With Type 2 Inflammation

Therapeutic Equivalence of CHF5993 pMDI 100/6/12.5 µg HFA-152a in Subjects With Mild to Moderate Asthma (TRECONY)

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy and Safety of Molnupiravir (MK-4482) in Non-Hospitalized Adults With COVID-19 at High Risk for Disease Progression

MOVe-NOW – A Phase 3 Clinical Study of Molnupiravir in Non-Hospitalized Adults With COVID-19 at High Risk for Disease Progression

A pragmatic, phase IV, randomized, open-label, multinational, multicentre, 2-arm parallel group, prospective study comparing efficacy and safety of Single Inhaler ICS/LABA/LAMA (beclometasone/formoterol fumarate/glycopyrronium bromide [87/5/9 pMDI {BD/FF/GB - 100/6/12.5 µg}]) vs Single Inhaler ICS/LABA (beclometasone dipropionate plus formoterol fumarate [200/6 pMDI {BD/FF - 200/6 µg}]) in asthma subjects.

A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety, and tolerability of cenerimod in adult subjects with moderate-to-severe systemic lupus erythematosus (SLE) on top of background therapy

LATITUDE-PsA-3002 – A Phase 3 Study of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis

TibuSURE – A Phase 2 Study of Tibulizumab in Adults With Systemic Sclerosis

An Open-Label, Randomized, Parallel-Group, Noninferiority Study to Evaluate IV vs SC Bimekizumab in PsA and/or axSpA

START SYNERGY – A Phase 2 Study of ELV001 in Active Rheumatoid Arthritis